Mark Lewis, Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, shared a post on X:
“Remarkably similar survivals for observation vs. maintenance PD1 inhibitors after cCR to immunotherapy in MSI-H/dMMR colorectal cancer.
So what are we increasing by continuing IO? (Cost, irAEs, our own therapeutic confidence?!)”
Other articles featuring Mark Lewis on OncoDaily.